Prescription drug · NDA
Combivir (Lamivudine and zidovudine) NDC 49702-202
Lamivudine 150 mg/1; Zidovudine 300 mg/1 · Tablet, Film coated · Oral · ViiV Healthcare Company
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 49702-202-18 | 4970202021849702020218 | 60 TABLET, FILM COATED in 1 BOTTLE (49702-202-18)Marketed from Oct 19, 2010 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Combivir
- Generic name (nonproprietary)
- lamivudine and zidovudine
- Active ingredients
- Lamivudine — 150 mg/1Zidovudine — 300 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- ViiV Healthcare CompanyNDC labeler code 49702
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 020857
- Marketing start
- Marketing end
- Other FDA classes
- Nucleoside Reverse Transcriptase Inhibitors (Mechanism)Nucleoside Reverse Transcriptase Inhibitors (Mechanism)
- Identifiers
- Product ID 49702-202_42a6587e-9322-4810-8c72-1dc40f3543d2SPL ID 42a6587e-9322-4810-8c72-1dc40f3543d2SPL set ID 16da660b-9981-4d24-a14a-94c7744fce4fRxCUI 200082, 213088UNII 2T8Q726O95, 4B9XT59T7SUPC 0349702202184
- Pharmacologic class
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N449702020218followed by a unit qualifier and the quantityPackage 49702-0202-18. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
COMBIVIR, a combination of 2 nucleoside analogues, is indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection. COMBIVIR, a combination of 2 nucleoside analogue reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 49702-202
- What is NDC 49702-202?
- 49702-202 is the product NDC for Combivir, Lamivudine 150 mg/1; Zidovudine 300 mg/1 tablet, film coated, listed with the FDA by ViiV Healthcare Company. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Combivir (Lamivudine and zidovudine).
- What is the active ingredient?
- Lamivudine, Zidovudine.
- Who is the labeler?
- ViiV Healthcare Company, NDC labeler code 49702. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Combivir?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.